Efficacy of neratinib in hormone receptor-positive (HR+) patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer (BC): subgroup analyses from the phase III ExteNET trial

Phase Iii ◽

Subgroup Analyses

Abstract P2-13-01: Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial

10.1158/1538-7445.sabcs18-p2-13-01 ◽

2019 ◽

Author(s):

M Gnant ◽

M Martin ◽

F-A Holmes ◽

C Jackisch ◽

SK Chia ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Hormone Receptor ◽

Early Stage ◽

Phase Iii ◽

Subgroup Analyses ◽

Breast Cancer Subgroup

Abstract P1-13-03: Effects of neratinib after trastuzumab-based adjuvant therapy in hormone receptor-positive HER2+ early-stage breast cancer: Exploratory analyses from the phase III ExteNET trial

10.1158/1538-7445.sabcs17-p1-13-03 ◽

2018 ◽

Author(s):

SKL Chia ◽

M Martin ◽

H Iwata ◽

B Moy ◽

AS Lalani ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Hormone Receptor ◽

Early Stage ◽

Phase Iii ◽

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Clinical Breast Cancer ◽

10.1016/j.clbc.2020.09.014 ◽

2020 ◽

Author(s):

Arlene Chan ◽

Beverly Moy ◽

Janine Mansi ◽

Bent Ejlertsen ◽

Frankie Ann Holmes ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Early Stage ◽

Phase Iii ◽

Her2 Positive ◽

Cost-Effectiveness of Letrozole Versus Tamoxifen as Initial Adjuvant Therapy in Hormone Receptor–Positive Postmenopausal Women with Early-Stage Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2007.n.018 ◽

2007 ◽

Vol 7 (8) ◽

pp. 608-618 ◽

Cited By ~ 19

Author(s):

Thomas E. Delea ◽

Jon Karnon ◽

Oleg Sofrygin ◽

Simu K. Thomas ◽

Natalie L. Papo ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Adjuvant Therapy ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Early Stage ◽

Faculty Opinions recommendation of Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736343660.793574002 ◽

2020 ◽

Author(s):

Lorenzo Livi ◽

Isacco Desideri

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Hormone Receptor ◽

Early Stage ◽

National Cancer Database ◽

Modern Era

Information needs of post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy

Patient Education and Counseling ◽

10.1016/j.pec.2013.03.019 ◽

2013 ◽

Vol 93 (1) ◽

pp. 114-121 ◽

Cited By ~ 5

Author(s):

Deb Feldman-Stewart ◽

Yolanda Madarnas ◽

Mihaela Mates ◽

Christine Tong ◽

Eva Grunfeld ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Information Needs ◽

Early Stage ◽

Adjuvant Endocrine Therapy ◽

Menopausal Women ◽

Post Menopausal

Factors Determining Anthracycline Use in Hormone Receptor Positive, Early-Stage Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.01.012 ◽

2019 ◽

Vol 19 (3) ◽

pp. e475-e480

Author(s):

Jordan Henderson ◽

Paul Adams ◽

Kimberly Barber

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Early Stage ◽

Abstract P2-18-01: Single modality adjuvant therapy with radiation (RT) alone or endocrine therapy (ET) alone in women ≥65 years with early stage, hormone receptor positive breast cancer treated with breast-conserving surgery: A population-based analysis

10.1158/1538-7445.sabcs19-p2-18-01 ◽

2020 ◽

Author(s):

Mira Goldberg ◽

Rinku Sutradhar ◽

Lawrence Paszat ◽

Timothy Whelan ◽

Sumei Gu ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Early Stage ◽

Breast Conserving Surgery ◽

Population Based ◽

Single Modality ◽

Positive Breast Cancer

PCN216 ADJUVANT CHEMOTHERAPY GUIDED BY A 21-GENE EXPRESSION ASSAY IN HORMONE-RECEPTOR POSITIVE EARLY-STAGE BREAST CANCER: USE OF SIMULATION MODELING TO EXTEND AND TRANSLATE CLINICAL TRIAL RESULTS INTO PRACTICE

Value in Health ◽

10.1016/j.jval.2019.04.338 ◽

2019 ◽

Vol 22 ◽

pp. S96-S97

Author(s):

J. Jayasekera ◽

J. Mandelblatt ◽

S. O'Neill ◽

C. Schechter

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Clinical Trial ◽

Adjuvant Chemotherapy ◽

Hormone Receptor ◽

Simulation Modeling ◽

Early Stage ◽

Clinical Trial Results

Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor–Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.07.052 ◽

2019 ◽

Vol 105 (4) ◽

pp. 795-802 ◽

Cited By ~ 15

Author(s):

Samantha M. Buszek ◽

Heather Y. Lin ◽

Isabelle Bedrosian ◽

Nina Tamirisa ◽

Gildy V. Babiera ◽

...

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Hormone Receptor ◽

Early Stage ◽

National Cancer Database ◽

Modern Era